NCT06356168 Virtual Reality in End Stage Kidney Disease
| NCT ID | NCT06356168 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | End Stage Kidney Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-03-30 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-03-30 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial to compare the social virtual reality and individual virtual reality in patients with end stage kidney disease who are hemodialysis. The main aim is to determine if there are differences in symptoms between the groups. Participants will use virtual reality glasses for 30-45 minutes during dialysis sessions for 4 weeks.
Eligibility Criteria
Inclusion Criteria * Diagnosis of end stage kidney disease with hemodialysis 3 times per week for at least 1 month Exclusion Criteria * Acutely ill * Active nausea * Epilepsy
Contact & Investigator
Lea Ann Matura, PhD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT06356168 clinical trial?
This trial is open to participants of all sexes, studying End Stage Kidney Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06356168 currently recruiting?
Yes, NCT06356168 is actively recruiting participants. Contact the research team at matura@nursing.upenn.edu for enrollment information.
Where is the NCT06356168 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT06356168 clinical trial?
NCT06356168 is sponsored by University of Pennsylvania. The principal investigator is Lea Ann Matura, PhD at University of Pennsylvania. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.